Literature DB >> 27339493

Effect of Pulmonary Vascular Pressures on Long-Term Outcome in Patients With Primary Mitral Regurgitation.

Amgad Mentias1, Krishna Patel1, Harsh Patel1, A Marc Gillinov1, Joseph F Sabik1, Tomislav Mihaljevic1, Rakesh M Suri1, L Leonardo Rodriguez1, Lars G Svensson1, Brian P Griffin1, Milind Y Desai2.   

Abstract

BACKGROUND: Primary mitral regurgitation (MR) is a growing health problem due to the aging population.
OBJECTIVES: The purpose of this study was to assess the impact of baseline pulmonary hypertension on long-term outcomes in patients with significant primary MR and preserved left ventricular ejection fraction (LVEF).
METHODS: We studied 1,318 patients with ≥3+ primary MR and LVEF ≥60% using echocardiography at rest; they were evaluated at our center from 2005 to 2008. Baseline clinical and echocardiography data were recorded, and the Society of Thoracic Surgeons (STS) score was calculated. The primary outcome was death.
RESULTS: Mean STS score was 3.98 ± 1%; 54% of patients were in New York Heart Association (NYHA) functional class I and 31% were in NYHA functional class II; and 18% had atrial fibrillation (AF). Mean LVEF, mitral effective regurgitant orifice, indexed LV end-systolic diameter (LVESD), and right ventricular systolic pressure (RVSP) were 62 ± 2%, 0.56 ± 0.30 cm(2), 1.6 ± 0.3 cm/m(2), and 37 ± 14 mm Hg, respectively. At 7.1 ± 2.0 years, 86% had mitral valve (MV) surgery. Death occurred in 130 (10%) patients. On Cox multivariable analysis, baseline RVSP, together with age, baseline NYHA functional class, pre-operative AF, coronary artery disease, and indexed LVESD were associated with a higher rate of longer term mortality (all p < 0.01), whereas MV surgery (as a time-dependent covariate) was associated with improved survival (p < 0.001). Addition of RVSP to the STS score significantly reclassified the risk for longer term mortality (integrated discrimination index: 0.07; p < 0.001); 77% patients who died had RVSP ≥35 mm Hg.
CONCLUSIONS: In patients with significant primary MR and preserved LVEF, baseline RVSP is independently associated with long-term survival. Impact of RVSP is progressive and not confined to those with the highest baseline values.
Copyright © 2016 American College of Cardiology Foundation. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  preserved ejection fraction; pulmonary hypertension; right ventricular systolic pressure; risk stratification

Mesh:

Year:  2016        PMID: 27339493     DOI: 10.1016/j.jacc.2016.03.589

Source DB:  PubMed          Journal:  J Am Coll Cardiol        ISSN: 0735-1097            Impact factor:   24.094


  13 in total

1.  Pulmonary hypertension: a long-term risk stratifier in primary mitral regurgitation.

Authors:  Mi-Jeong Kim; Hae Ok Jung
Journal:  Ann Transl Med       Date:  2016-12

2.  Is pulmonary artery pressure a trigger of adverse outcome in mitral regurgitation?

Authors:  Iside Scarfò; Giovanni La Canna
Journal:  Ann Transl Med       Date:  2016-12

3.  Markers of increased risk in primary mitral regurgitation.

Authors:  Amgad Mentias; Milind Y Desai
Journal:  Ann Transl Med       Date:  2017-08

Review 4.  Mitral Valve Disease: a Comprehensive Review.

Authors:  Serge C Harb; Brian P Griffin
Journal:  Curr Cardiol Rep       Date:  2017-08       Impact factor: 2.931

5.  Prevalence and survival associated with pulmonary hypertension after mitral valve replacement: National echocardiography database of Australia study.

Authors:  Nicholas Collins; Stuart Sugito; Allan Davies; Andrew Boyle; Aaron Sverdlov; John Attia; Simon Stewart; David Playford; Geoff Strange
Journal:  Pulm Circ       Date:  2022-10-01       Impact factor: 2.886

Review 6.  Pulmonary Hypertension in Patients Eligible for Transcatheter Mitral Valve Repair: Prognostic Impact and Clinical Implications.

Authors:  Evin Yucel; Rasha Al-Bawardy; Philippe B Bertrand
Journal:  Curr Treat Options Cardiovasc Med       Date:  2019-09-10

7.  Exercise capacity in asymptomatic patients with significant primary mitral regurgitation: independent effect of global longitudinal left ventricular strain.

Authors:  Amgad Mentias; Alaa Alashi; Peyman Naji; A Marc Gillinov; L Leonardo Rodriguez; Tomislav Mihaljevic; Rakesh M Suri; Richard A Grimm; Lars G Svensson; Brian P Griffin; Milind Y Desai
Journal:  Cardiovasc Diagn Ther       Date:  2018-08

8.  Increased Mortality in Patients With Preoperative and Persistent Postoperative Pulmonary Hypertension Undergoing Mitral Valve Surgery for Mitral Regurgitation: A Cohort Study.

Authors:  Michael V Genuardi; Daniel Shpilsky; Adam Handen; Gabrielle VanSpeybroeck; Ann Canterbury; Michael Lu; Kayle Shapero; Ricardo A Nieves; Floyd Thoma; Suresh R Mulukutla; João L Cavalcante; Stephen Y Chan
Journal:  J Am Heart Assoc       Date:  2021-02-18       Impact factor: 5.501

9.  Pulmonary Hypertension in Aortic and Mitral Valve Disease.

Authors:  Micha T Maeder; Lukas Weber; Marc Buser; Marc Gerhard; Philipp K Haager; Francesco Maisano; Hans Rickli
Journal:  Front Cardiovasc Med       Date:  2018-05-23

10.  Echocardiographic assessment of pulmonary hypertension: a guideline protocol from the British Society of Echocardiography.

Authors:  Daniel X Augustine; Lindsay D Coates-Bradshaw; James Willis; Allan Harkness; Liam Ring; Julia Grapsa; Gerry Coghlan; Nikki Kaye; David Oxborough; Shaun Robinson; Julie Sandoval; Bushra S Rana; Anjana Siva; Petros Nihoyannopoulos; Luke S Howard; Kevin Fox; Sanjeev Bhattacharyya; Vishal Sharma; Richard P Steeds; Thomas Mathew
Journal:  Echo Res Pract       Date:  2018-09
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.